Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as adjuvant therapy for patients with HER2+ early breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract: LBA500: APHINITY trial (BIG 4-11): Pertuzumab as Adjuvant Therapy in HER2-Positive Early Breast Cancer.
Advertisement